Article
Medicine, General & Internal
Margherita Zen, Laura Salmaso, Claudio Barbiellini Amidei, Ugo Fedeli, Stefania Bellio, Luca Iaccarino, Andrea Doria, Mario Saia
Summary: This population-based study aimed to assess mortality rates, standardized mortality ratios, and causes of death in systemic lupus erythematosus (SLE). The study analyzed administrative health databases in the Veneto Region, Italy, and found that SLE mortality is higher than that of the general population, especially in younger patients. The main causes of death were cardiovascular diseases and cancer.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Rheumatology
Irene E. M. Bultink, Frank de Vries, Ronald F. van Vollenhoven, Arief Lalmohamed
Summary: Patients with SLE in the UK have a 1.8-fold increased mortality rate compared to the general population, with the highest risk for those aged 18-39 years old; low-dose HCQ reduces the risk of mortality by 45%.
Review
Medicine, General & Internal
Wenjun Gou, Yan Hong Tuo
Summary: This study compared the mortality and causes of mortality in patients with lupus nephritis who received hemodialysis (HD) or peritoneal dialysis (PD). The results showed that the risk of mortality was similar between the two dialysis methods, and there were no significant differences in the causes of death, including cardiovascular, infective, respiratory, SLE flare up, and other causes.
Article
Medicine, General & Internal
Victor Moreno-Torres, Carlos Tarin, Guillermo Ruiz-Irastorza, Raquel Castejon, Angela Gutierrez-Rojas, Ana Royuela, Pedro Duran-del Campo, Susana Mellor-Pita, Pablo Tutor, Silvia Rosado, Enrique Sanchez, Maria Martinez-Urbistondo, Carmen de Mendoza, Miguel Yebra, Juan-Antonio Vargas
Summary: Over the past two decades, there has been an increase in admissions for SLE patients, however, the percentage of SLE as a cause of admission has decreased. On the contrary, cardiovascular disease, infections, and neoplasm have become the main reasons for admissions and mortality.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Fanny Urbain, Maharajah Ponnaiah, Farid Ichou, Marie Lhomme, Clement Materne, Sophie Galier, Julien Haroche, Eric Frisdal, Alexis Mathian, Herve Durand, Micheline Pha, Miguel Hie, Anatol Kontush, Philippe Cluzel, Philippe Lesnik, Zahir Amoura, Maryse Guerin, Fleur Cohen Aubart, Wilfried Le Goff
Summary: This study uncovers the contribution of disturbed metabolism to the presence of coronary artery calcium and the associated risk of coronary heart disease in patients with systemic lupus erythematosus (SLE). Identification of novel lipid and metabolite biomarkers may help stratifying patients for reducing cardiovascular disease morbidity and mortality in SLE.
Article
Rheumatology
Sarfaraz Hasni, Yenealem Temesgen-Oyelakin, Michael Davis, Jun Chu, Elaine Poncio, Mohammad Naqi, Sarthak Gupta, Xinghao Wang, Christopher Oliveira, Dillon Claybaugh, Amit Dey, Shajia Lu, Philip Carlucci, Monica Purmalek, Zerai G. Manna, Yinghui Shi, Isabel Ochoa-Navas, Jinguo Chen, Amrita Mukherjee, Kyu Lee Han, Foo Cheung, Galina Koroleva, Yasmine Belkaid, John S. Tsang, Richard Apps, Donald E. Thomas, Theo Heller, Massimo Gadina, Martin P. Playford, Xiaobai Li, Nehal N. Mehta, Mariana J. Kaplan
Summary: The study aimed to investigate the effects of the peroxisome proliferator activated receptor-gamma agonist pioglitazone (PGZ) on vascular function and cardiometabolic parameters in SLE patients. The results showed that PGZ significantly improved vascular stiffness and metabolic parameters in SLE patients.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Weike Luo, Filipa Farinha, David A. Isenberg, Anisur Rahman
Summary: In this study, non-Caucasian ethnicity and younger age at diagnosis are associated with the risk of developing LN in SLE patients. There is evidence of improvement in survival among SLE patients over time.
Review
Medicine, General & Internal
Johan Frostegard
Summary: The prognosis in systemic lupus erythematosus (SLE) has improved, but cardiovascular disease (CVD) still remains a significant clinical problem. Atherosclerosis and antiphospholipid antibody syndrome are the main underlying causes of CVD in SLE. Inflammation and low levels of anti-phosphorylcholine also contribute to the increased risk of CVD in SLE. Close monitoring and treatment of both traditional and non-traditional risk factors are important.
JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Rheumatology
George C. Drosos, Daisy Vedder, Eline Houben, Laura Boekel, Fabiola Atzeni, Sara Badreh, Dimitrios T. Boumpas, Nina Brodin, Ian N. Bruce, Miguel Angel Gonzalez-Gay, Soren Jacobsen, Gyorgy Kerekes, Francesca Marchiori, Chetan Mukhtyar, Manuel Ramos-Casals, Naveed Sattar, Karen Schreiber, Savino Sciascia, Elisabet Svenungsson, Zoltan Szekanecz, Anne-Kathrin Tausche, Alan Tyndall, Vokko van Halm, Alexandre Voskuyl, Gary J. Macfarlane, Michael M. Ward, Michael T. Nurmohamed, Maria G. Tektonidou
Summary: This study developed recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, emphasizing the importance of regular screening and management of modifiable CVR factors as well as patient education. The recommendations covered CVR prediction tools, interventions on traditional CVR factors, and interventions on disease-related CVR factors.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Chunhuan Lao, Douglas White, Kannaiyan Rabindranath, Philippa Van Dantzig, Donna Foxall, Ross Lawrenson
Summary: This study aimed to assess the mortality rate of SLE patients and examine potential variations by subgroup. The results showed that SLE patients had a four times higher risk of death compared with the general population. Maori individuals had worse survival outcomes compared to others.
Article
Cardiac & Cardiovascular Systems
Holly Ryan, Laurence Morel, Erika Moore
Summary: Vascular inflammation caused by overly activated immune cells is a significant factor contributing to morbidity and mortality in systemic lupus erythematosus (SLE). There are several mouse models currently used to study the pathogenesis of SLE, each with different mechanisms. The diversity of these models allows for the investigation of different aspects of the disease. To better understand the mechanisms of vascular inflammation in SLE and assist future researchers in selecting appropriate mouse models to study cardiovascular complications, it is suggested to directly compare vascular inflammation among different mouse models of SLE. Additionally, the use of in vitro vascular assays is proposed to further investigate prevalent vascular inflammation processes in different mouse models of SLE.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Rheumatology
Alexandra Legge, Alicia Malone, John G. Hanly
Summary: The SLICC frailty index (SLICC-FI) has been validated in a prevalent cohort of individuals with longstanding SLE, showing that higher baseline SLICC-FI values are associated with increased mortality risk and damage accrual.
Article
Rheumatology
Karim Sacre, Evelyne Vinet, Christian A. Pineau, Arielle Mendel, Fares Kalache, Louis-Pierre Grenier, Thao Huynh, Sasha Bernatsky
Summary: NT-proBNP is associated with cardiovascular damage in SLE patients and could serve as a biomarker for cardiovascular damage. NT-proBNP levels are associated with hypertension, dyslipidemia, age, smoking history, reduced eGFR, prior pericarditis/pleuritis, and aPL antibodies.
Review
Medicine, General & Internal
Sigrid Reppe Moe, Hilde Haukeland, Oyvind Molberg, Karoline Lerang
Summary: Research on outcomes of Systemic Lupus Erythematosus (SLE) shows that the standardized mortality ratio ranges from 1.9 to 4.6, with cardiovascular disease being the most common cause of death and ESRD progressing in 5-11% of all SLE patients. There is currently no data supporting an increased incidence of cancer in SLE patients. Further population-based studies are needed, especially inception studies with control groups and follow-up times over 15 years.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Rheumatology
Lisa Zhu, Manpreet Singh, Sonia Lele, Lori Sahakian, Jennifer Grossman, Bevra Hahn, Maureen McMahon
Summary: This study assessed the validity of QRISK3 in predicting cardiovascular risk in SLE patients compared to other risk models. The results showed that both QRISK3 and PREDICTS performed better than traditional risk scoring methods in predicting cardiovascular disease risk in SLE patients.
LUPUS SCIENCE & MEDICINE
(2022)